REGN Oct 2024 1100.000 put
| Previous close | 66.80 |
| Open | 66.80 |
| Bid | 86.40 |
| Ask | 92.70 |
| Strike | 1,100.00 |
| Expiry date | 2024-10-18 |
| Day's range | 66.80 - 66.80 |
| Contract range | N/A |
| Volume | |
| Open interest | 524 |
ZacksSanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
Insider MonkeyJim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’
We recently compiled a list of the Cramer’s Morning Thoughts: 20 Stocks to Watch. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) stands against the other stocks to watch according to Jim Cramer. In a recent episode of Mad Money, Jim Cramer explains that if you’re investing with […]
BloombergRegeneron Shares Head for Worst Month Since 2019 on Legal Ruling
(Bloomberg) -- Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2019 after a legal setback that opens the door to an early launch of a competing therapy to the drugmaker’s blockbuster eye treatment, Eylea.Most Read from BloombergA 7,000-Year-Old City Emerges as a Haven from Dubai’s Sky-High RentsClimate Migrants Stand to Overwhelm World’s MegacitiesNew Rowhouses in London That Offer a Bridge to the 19th CenturyVanderbilt Leases Struggling NYC Seminary for
